UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-QSB
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2004.
[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT FOR THE
TRANSITION PERIOD FROM _______________ to______________
Commission file number: 0-16159
LECTEC CORPORATION
(Exact name of small business issuer as specified in its charter)
Minnesota 41-1301878
- --------------------------------------- --------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
10701 Red Circle Drive, Minnetonka, Minnesota 55343
- ------------------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
(952) 933-2291
---------------------------
(Issuer's telephone number)
Not Applicable
----------------------------------------------------
(Former name, former address and former fiscal year,
if changed from last report)
Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days:
Yes [X] No [ ]
The number of shares outstanding of the issuer's common stock as of August 16,
2004 was 4,017,994 shares.
Transitional Small Business Disclosure Format (Check one):
Yes [ ] No [X]
LECTEC CORPORATION
REPORT ON FORM 10-QSB FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2004
TABLE OF CONTENTS
PART I - FINANCIAL INFORMATION
Item 1. Condensed Financial Statements and Notes to Condensed Financial Statements (unaudited) I-1
Item 2. Management's Discussion and Analysis or Plan of Operation I-10
Item 3. Controls and Procedures I-13
PART II - OTHER INFORMATION
Item 1. Legal Proceedings II-1
Item 2. Changes in Securities and Small Business Issuer Purchases of Equity Securities II-1
Item 3. Defaults Upon Senior Securities II-1
Item 4. Submission of Matters to a Vote of Security Holders II-1
Item 5. Other Information II-1
Item 6. Exhibits and Reports on Form 8-K II-1
Signature Page II-3
FORWARD-LOOKING STATEMENTS
From time to time, in reports filed with the Securities and Exchange
Commission (including this Form 10-QSB), in press releases, and in other
communications to shareholders or the investment community, the Company may
provide forward-looking statements concerning possible or anticipated future
results of operations or business developments which are typically preceded by
the words "believes", "expects", "anticipates", "intends", "will", "may",
"should" or similar expressions. Such forward-looking statements are subject to
risks and uncertainties which could cause results or developments to differ
materially from those indicated in the forward-looking statements. Such risks
and uncertainties include, but are not limited to, the Company's dependence on
major customers and the continuance of prepayment terms; competitive forces
including new products or pricing pressures; impact of interruptions to
production; dependence on key personnel; need for regulatory approvals; changes
in governmental regulatory requirements or accounting pronouncements; ability to
satisfy funding and capital requirements for operating needs, expansion or
capital expenditures and the matters discussed on the "Cautionary Statements"
filed as Exhibit 99.01 to the Company's Report on Form 10-KSB for the year ended
December 31, 2003.
PART I - FINANCIAL INFORMATION
ITEM 1 - CONDENSED FINANCIAL STATEMENTS AND NOTES TO CONDENSED FINANCIAL
STATEMENTS
LECTEC CORPORATION
CONDENSED BALANCE SHEETS
(Unaudited)
June 30, December 31,
2004 2003
----------- ------------
ASSETS
CURRENT ASSETS:
Cash and cash equivalents $ 891,642 $ 483,844
Trade and other receivables, net of allowances of $36,197
and $46,000 at June 30, 2004 and December 31, 2003 652 203,866
Inventories:
Raw materials 450,722 465,050
Work-in-process 90,081 41,354
Finished goods 296,062 587,065
---------- ----------
836,865 1,093,469
Prepaid expenses and other 72,153 220,813
---------- ----------
Total current assets 1,801,312 2,001,992
PROPERTY, PLANT AND EQUIPMENT - AT COST, NET 416,650 477,063
OTHER ASSETS:
Patents and trademarks, less accumulated amortization of $1,352,308
and $1,305,180 at June 30, 2004 and December 31, 2003 195,940 211,595
---------- ----------
$2,413,902 $2,690,650
========== ==========
See notes to condensed financial statements.
I - 1
LECTEC CORPORATION
CONDENSED BALANCE SHEETS - CONTINUED
(Unaudited)
June 30, December 31,
2004 2003
----------- ------------
LIABILITIES AND SHAREHOLDERS' DEFICIT
CURRENT LIABILITIES:
Current maturities of long-term obligations 231,114 232,564
Accounts payable 218,717 336,749
Accrued expenses 366,564 361,828
Reserve for sales returns and credits 188,407 140,557
Customer deposits 1,402,613 1,710,282
------------ ------------
Total current liabilities 2,407,415 2,781,980
LONG-TERM OBLIGATIONS, LESS CURRENT MATURITIES 57,982 62,438
COMMITMENTS AND CONTINGENCIES - -
SHAREHOLDERS' DEFICIT:
Common stock, $.01 par value: 15,000,000 shares authorized;
4,017,994 and 3,979,327 shares issued and outstanding at
June 30, 2004 and December 31, 2003, respectively 40,180 39,793
Additional paid-in capital 11,569,063 11,550,743
Accumulated deficit (11,660,738) (11,744,304)
------------ ------------
(51,495) (153,768)
------------ ------------
$ 2,413,902 $ 2,690,650
============ ============
See notes to condensed financial statements.
I - 2
LECTEC CORPORATION
CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)
Three months ended Six months ended
June 30, June 30,
------------------------------ -------------------------------
2004 2003 2004 2003
----------- ----------- ----------- ------------
Net sales $ 1,520,146 $ 1,624,416 $ 3,999,446 $ 3,270,106
Cost of goods sold 1,146,872 1,233,409 2,880,407 2,387,800
----------- ----------- ----------- -----------
Gross profit 373,274 391,007 1,119,039 882,306
Operating expenses
Sales and marketing 31,103 165,598 99,051 363,675
General and administrative 219,105 555,430 670,006 1,037,795
Research and development 121,561 97,249 268,801 198,781
Loss on sale of building - - - 52,375
----------- ----------- ----------- -----------
371,769 818,277 1,037,858 1,652,626
----------- ----------- ----------- -----------
Income (loss) from operations 1,505 (427,270) 81,181 (770,320)
Other income (expenses)
Interest expense (5,181) (5,721) (9,972) (24,653)
Other, net 12,515 (557) 12,357 1,939
----------- ----------- ----------- -----------
Net income (loss) $ 8,839 $ (433,548) $ 83,566 $ (793,034)
=========== =========== =========== ===========
Net income (loss) per share:
Basic $ 0.00 $ (0.11) $ 0.02 $ (0.20)
=========== =========== =========== ===========
Diluted $ 0.00 $ (0.11) $ 0.02 $ (0.20)
=========== =========== =========== ===========
Weighted average shares outstanding:
Basic 4,016,089 3,966,395 3,997,708 3,966,395
=========== =========== =========== ===========
Diluted 4,047,985 3,966,395 4,094,361 3,966,395
=========== =========== =========== ===========
See notes to condensed financial statements.
I - 3
LECTEC CORPORATION
STATEMENTS OF CASH FLOWS
(Unaudited)
Six months ended June 30,
-------------------------
2004 2003
--------- ----------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) $ 83,566 $(793,034)
Adjustments to reconcile net income (loss) to net
cash provided by (used in) operating activities:
Loss on sale of building - 52,375
Depreciation and amortization 182,091 271,479
Changes in operating assets and liabilities:
Trade and other receivables 203,214 137,525
Inventories 256,604 (333,878)
Prepaid expenses and other 148,660 80,247
Accounts payable (118,032) 145,507
Accrued expenses and other 52,586 (266,155)
Customer deposits (307,669) 537,302
--------- ---------
Net cash provided by (used in) operating activities 501,020 (168,632)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property, plant and equipment (74,550) (11,005)
Proceeds from sale of property, plant and equipment - 845,000
Investment in patents and trademarks (31,473) (43,993)
--------- ---------
Net cash provided by (used in) investing activities (106,023) 790,002
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of mortgage note payable - (820,000)
Repayment of long-term obligations (5,906) (61,674)
Proceeds from exercise of stock options 18,707 -
--------- ---------
Net cash provided by (used in) financing activities 12,801 (881,674)
--------- ---------
Net increase (decrease) in cash and cash equivalents 407,798 (260,304)
Cash and cash equivalents at beginning of period 483,844 671,588
--------- ---------
Cash and cash equivalents at end of period $ 891,642 $ 411,284
========= =========
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid during the period for:
Interest expense $ 3,299 $ 36,785
SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING ACTIVITIES:
Fair value of warrants issued in connection with the sale of building $ - $ 158,000
Value of free rent received in connection with the sale of building $ - $ 228,512
See notes to condensed financial statements.
I - 4
LECTEC CORPORATION
NOTES TO CONDENSED FINANCIAL STATEMENTS
JUNE 30, 2004 AND 2003
(Unaudited)
(1) GENERAL
The accompanying condensed financial statements include the accounts of
LecTec Corporation (the "Company") as of June 30, 2004 and December 31, 2003 and
for the three and six month periods ended June 30, 2004 and 2003. The Company's
condensed financial statements have been prepared in accordance with accounting
principles generally accepted in the United States of America and should be read
in conjunction with the Company's Annual Report on Form 10-KSB for the year
ended December 31, 2003. The interim condensed financial statements are
unaudited and in the opinion of management, reflect all adjustments necessary
for a fair presentation of results for the periods presented. Results for
interim periods are not necessarily indicative of results for the year.
(2) BUSINESS SUMMARY AND CRITICAL ACCOUNTING POLICIES
BUSINESS SUMMARY
The Company is a health care and consumer products company that develops
and manufactures products based on its advanced skin interface technologies.
Primary products include a complete line of over-the-counter ("OTC") therapeutic
patches. The Company is principally a contract manufacturer of topical
therapeutic patches. All of the products manufactured by the Company are
designed to be effective, safe, and highly compatible with skin.
CRITICAL ACCOUNTING POLICIES
Some of the Company's most critical accounting policies include:
Revenue Recognition. For domestic sales, revenue is recognized when the
product has been shipped to the customer and collection is probable. For
international sales, revenue is recognized when the product is received by the
customer and collection is probable.
Impairment of Long-Lived Assets. The carrying value of long-lived assets
is reviewed periodically or when factors indicating impairment are present.
Projected discounted cash flows are used when reviewing these assets. The amount
of impairment loss is measured as the amount by which the carrying value of the
assets exceeds the fair value of the assets. Based on the Company's decision to
wind down manufacturing operations, the Company reviewed its long-lived assets
for impairment at June 30, 2004. No impairment was noted as a result of this
review.
Inventories. Inventories are stated at the lower of cost (determined on a
first-in, first-out basis) or market.
LIQUIDITY, GOING CONCERN, AND WIND DOWN OF MANUFACTURING OPERATIONS
The accompanying financial statements have been prepared in conformity
with accounting principles generally accepted in the United States of America,
which contemplate continuation of the Company as a going concern. However, the
Company has experienced recurring negative cash flows from operations and net
losses resulting in an accumulated deficit of $11,660,738 as of June 30, 2004
and, as of that date, the Company's current liabilities exceeded its current
assets by $606,103. In addition, during 2004 the Company's two largest customers
are going to discontinue their supply arrangements with the Company. It is
management's intent to wind down its manufacturing operations, sell off
manufacturing assets, renegotiate its facility leases and fund continuing
operations with royalty income from licensing agreements or from other income
derived from protection of rights pertaining to the Company's intellectual
property.
I-5
In view of the matters described in the preceding paragraph,
recoverability of a major portion of the recorded asset amounts shown in the
accompanying balance sheet is dependent upon profitable operations of the
Company and the continuation of product prepayment terms with the Company's
largest customer (Novartis Consumer Health, Inc.). The financial statements do
not include any adjustments relating to the recoverability and classification of
recorded asset amounts or amounts and classification of liabilities that might
be necessary should the Company cease operations or be unable to continue in
existence.
In connection with the pending cessation of manufacturing operations, the
Company has implemented employee reduction and retention programs to reduce the
number of employees needed to support the wind down of manufacturing operations
while retaining those employees who are critical to that process and to managing
the Company's ongoing licensing agreements and intellectual property portfolio.
The Company is exploring its alternatives with respect to the sale of its
manufacturing assets, the renegotiation or termination of its leases and other
contractual obligations, and other adjustments resulting directly from the
Company's exit from contract manufacturing operations. In addition, the Company
will be considering other possible fundamental changes in future periods that
could include, among other things, a sale of its remaining assets or of the
business as a whole.
At June 30, 2004, the Company's cash resources are insufficient to fund
operations for the foreseeable future without the continuation of prepayment
terms on future product orders with the Company's largest customer ("Novartis").
On July 19, 2004, the Company entered into a new supply and licensing agreement
("Agreement") with Novartis, effective January 1, 2004. See the discussion under
"Subsequent Event" in Note 11 of Part I, Item 1 below for a description of this
new Agreement. Any cash obtained as a result of the Agreement will be used to
fund continuing operations. However, there can be no assurance that the Company
will receive sufficient cash to fund continuing operations. Furthermore, the
Company does not have any other financing resources in place from which it can
borrow or obtain additional working capital. These factors raise substantial
doubt about its ability to continue as a going concern.
There can be no assurance that sources of additional capital or funds will
be available on terms acceptable to the Company, if at all. If the Company is
not successful in obtaining additional funding, or in continuing prepayment
terms on future product orders with its largest customer, it may not be able to
continue as a going concern.
(3) NET INCOME (LOSS) PER SHARE
The Company's basic net income (loss) per share amounts have been computed
by dividing net income (loss) by the weighted average number of outstanding
common shares. The Company's diluted net income (loss) per share amounts have
been computed by dividing net income (loss) by the weighted average number of
outstanding common shares and common share equivalents, when dilutive. Options
and warrants to purchase 551,528 and 427,195 shares of common stock with
weighted average exercise prices of $2.75 and $3.33 were outstanding during the
three and six months ended June 30, 2004, respectively, but were excluded from
the calculation because they were antidilutive. Options and warrants to purchase
1,315,945 and 1,252,680 shares of common stock with weighted average exercise
prices of $1.89 and $1.95 were outstanding during the three and six months ended
June 30, 2003, respectively, but were excluded from the calculation because they
were antidilutive.
(4) SEGMENTS
The Company operates its business in one reportable segment - the
manufacture and sale of products based on advanced skin interface technologies.
The Company also has only one major product line - therapeutic topical skin
patch products for the consumer market. The Company's products have similar
economic characteristics, technology, manufacturing processes, and regulatory
environments. Customers and distribution and marketing strategies vary within
individual products as well as overlap between products.
(5) LONG-TERM OBLIGATIONS
In May 2002, the Company entered into a $220,000 promissory note ("Recall
Debt Note") with Novartis related to the costs incurred by the customer
associated with resolving a packaging issue that previously had been recorded as
a sales credit by the Company. The principal balance of the Recall Debt
I-6
Note was originally due in December 2003 and is subject to ongoing negotiations
regarding payment. Interest is accrued at the prime rate plus 2.0% (effective
rate of 6.0% at June 30, 2004). The Recall Debt Note is collateralized by
substantially all of the Company's assets.
On July 19, 2004, the Company entered into a new supply and licensing
agreement ("Agreement") with Novartis, effective January 1, 2004. Under the
Agreement, Novartis released the recall debt of $250,000 ($220,000 principal and
$30,000 of accrued interest) and forgave and relinquished any claim for payment
of any of the obligations of the Company under the Recall Debt Note. See the
discussion under "Subsequent Event" in Note 11 of Part I, Item 1 below for a
description of this new Agreement.
The Company has capital lease obligations related to its leased corporate
facility as well as leased office and production equipment. Capital lease
obligations are due through June 2013 in various monthly installments up to $879
and carry interest up to 19.1%. The obligations are generally collateralized by
equipment underlying the leases. At June 30, 2004, the principal balance
remaining on capital lease obligations was $69,096.
(6) CUSTOMER DEPOSITS
The Company receives advance payments from customers for future product
orders and records these amounts as liabilities. At June 30, 2004, the Company
had recorded customer deposits of $1,402,613.
(7) SALE OF CORPORATE FACILITY
In February 2003, the Company sold its corporate facility in Minnetonka,
Minnesota for an aggregate purchase price of $910,270, repaid the balance of the
mortgage note payable of $820,000, and recorded a loss on sale of $52,375 during
the quarter ended March 31, 2003. In connection with the sale, the Company
entered into a lease of its corporate facility which granted the Company free
rent for the twelve months following the sale/leaseback transaction and
thereafter extends the lease at costs based on current market conditions. The
lease has been extended to February 2005 at a base rent per month of $10,853.
Also in connection with the sale, the purchaser received a warrant to purchase
200,000 shares of common stock at $0.90 per share.
(8) STOCK BASED COMPENSATION
In July 2002, 803,958 stock options with a weighted average exercise price
of $4.54 per share were re-priced to $0.81 per share. At June 30, 2004, 176,000
of these options were outstanding and 174,333 were exercisable. No compensation
expense was recorded by the Company in connection with the re-pricing because
the exercise price exceeded the market price on the date of the re-pricing.
During the first quarter ended March 31, 2004, the market price was higher than
the exercise price and the Company recorded compensation expense of $76,765.
However, during the six months ended June 30, 2004 the ending market price for
the Company's common stock was below the exercise price of the re-priced
options. Accordingly, the Company recorded compensation income of $76,765 during
the second quarter ended June 30, 2004, thereby having no compensation expense
or income for the six months ended June 30, 2004.
The Company utilizes the intrinsic value method of accounting for stock
based employee compensation plans. All options granted had an exercise price
equal to the market value of the underlying common stock on the date of grant
and no compensation cost related to stock option grants is reflected in net
income or loss for the three and six months ended June 30, 2004 and 2003. The
following table illustrates the effect on net income or loss if the Company had
applied the fair value recognition provisions of Financial Accounting Standards
Board ("FASB") Statement No. 123, Accounting for Stock-Based Compensation:
I-7
Three months ended Six months ended
June 30, June 30,
-------- --------
2004 2003 2004 2003
---- ---- ---- ----
Net income (loss), as reported ..... $ 8,839 $(433,548) $ 83,566 $(793,034)
Less: compensation expense
determined under the fair value
method ........................... (26,771) (50,703) (53,576) (100,657)
-------- --------- -------- ---------
Pro-forma net income (loss) ........ $(17,932) $(484,251) $ 29,990 $(893,691)
======== ========= ======== =========
Net income (loss) per share:
Basic, as reported ............... $ 0.00 $ (0.11) $ 0.02 $ (0.20)
Basic, pro-forma ................ (0.00) (0.12) 0.01 (0.23)
Diluted, as reported ............. 0.00 (0.11) 0.02 (0.20)
Diluted, pro-forma .............. (0.00) (0.12) 0.01 (0.23)
The pro-forma information above should be read in conjunction with the
related historical information.
The weighted average fair value of options granted during the six months
ended June 30, 2004 and 2003 was $1.09 and $0.44, respectively. The fair value
of each option grant is estimated on the date of grant using the Black-Scholes
option valuation model with the following weighted-average assumptions used for
all grants during the six months ended June 30, 2004 and 2003; zero dividend
yield, expected volatility of 182% and 153%, risk-free interest rates of 2.72%
and 2.85% and expected lives of 3.0 and 4.0 years, respectively.
Management believes the Black-Scholes option valuation model currently
provides the best estimate of fair value. However, the Black-Scholes option
valuation model was developed for use in estimating the fair value of traded
options, which have no vesting restrictions and are fully transferable. In
addition, option valuation models require the input of several subjective
assumptions. The Company's employee and director stock options have
characteristics different from those of traded options, and changes in the
subjective input assumptions can materially affect the fair value estimate.
(9) INCOME TAXES
No federal or state income taxes were provided for the three and six
months ended June 30, 2004, due to available tax credit and net operating loss
carryforwards to the current periods. The provision for income tax benefits for
the three and six months ended June 30, 2004 and 2003 has been offset by a
valuation allowance for deferred taxes.
(10) RECENT ACCOUNTING PRONOUNCEMENTS
In November 2002, the FASB issued Financial Interpretations No. 45 (FIN
45), "Guarantor's Accounting and Disclosure Requirements for Guarantees,
Including Indirect Guarantees of Indebtedness of Others". FIN 45 addresses the
disclosure requirements of a guarantor in its interim and annual financial
statements about its obligations under certain guarantees that it has issued.
FIN 45 also requires a guarantor to recognize, at the inception of a guarantee,
a liability for the fair value of the obligation undertaken in issuing the
guarantee. The disclosure requirements of FIN 45 were effective for the Company
for the year ended December 31, 2002. The liability recognition requirements are
applicable prospectively to all guarantees issued or modified after January 1,
2003. The Company currently does not have guarantees within the scope of this
pronouncement, and therefore this interpretation is not anticipated to have an
impact on the Company's financial position or results of operations.
In January 2003, the FASB issued FIN 46, "Consolidation of Variable
Interest Entities". FIN 46 is an interpretation of Accounting Research Bulletin
No. 51, "Consolidated Financial Statements," and addresses consolidation by
business enterprises of variable interest entities. FIN 46 applies immediately
to variable interest entities created or obtained before January 31, 2003 and
applies in the first fiscal year or interim period beginning after June 15,
2003, to variable interest entities in which an enterprise holds a variable
I-8
interest that it acquired before February 1, 2003. This interpretation is not
anticipated to have an impact on the Company's consolidated financial position
or results of operations.
(11) SUBSEQUENT EVENT
On July 19, 2004, the Company entered into a supply and licensing
agreement, effective as of January 1, 2004 (the "Agreement"), with Novartis
Consumer Health, Inc. ("Novartis"). The Agreement replaces the Company's prior
supply and licensing agreement with Novartis dated May 8, 2002. The Agreement
requires the Company to manufacture, sell and deliver to Novartis vapor patches
for sale to the pediatric market in the United States, Canada and Mexico. Under
the Agreement, Novartis has the option until March 31, 2005 to extend the use of
vapor patches to the adult cough/cold category in the United States, Canada and
Mexico at no additional cost and under the same terms and conditions as set
forth in the Agreement. In order to provide the Company with working capital
funds necessary to enable it to manufacture and deliver vapor patches to
Novartis in accordance with the Agreement, Novartis has or will advance up to
$2,000,000 at any time to the Company for use by the Company to pay current
accounts payable and expenses incurred exclusively for the manufacture and
delivery of vapor patches. In consideration of the advanced funds, the Company
executed and delivered to Novartis a promissory note in the principal amount of
$2,000,000 and a security agreement. Under the security agreement, the Company
has pledged substantially all of its assets to secure the $2,000,000 advance
payment note. The advance payment note will be repaid by the Company from time
to time by the delivery to Novartis of vapor patches under the Agreement.
Under the Agreement, the Company has granted to Novartis an exclusive
license (the "License") to all of the intellectual property of the Company to
the extent that it is used or useful in the production of the vapor patches
being supplied under the Agreement for a fee of $1,065,000, which is being paid
to the Company by Novartis as follows: (1) release of $250,000 in debt on July
19, 2004, (2) payment of $407,500 in cash on July 22, 2004, and (3) payment of
$407,500 in cash on October 1, 2004. The License began on July 19, 2004, and
will continue for the duration of any patents included in the licensed
intellectual property and, with respect to all other elements of the licensed
intellectual property, for the maximum duration permitted under applicable law.
Upon the expiration of the patents included in the licensed intellectual
property, Novartis will have a non-revocable, perpetual, fully paid-up license
to the intellectual property used or useful in the production of vapor patches
for the pediatric market (and the adult cough/cold market if Novartis has
exercised its option in that regard). Commencing on January 1, 2005, Novartis is
required by the Agreement to pay royalties, at an agreed upon percentage, to the
Company based on net semi-annual sales of vapor patches by Novartis for each
year the License is in effect.
The Agreement will continue in effect until February 5, 2005, except that
the provisions relating to the License will continue in effect until the
conclusion of the term of the License. The Company may not assign or otherwise
transfer the Agreement (other than to an affiliate) without the prior written
consent of Novartis, except that the Company may assign the Agreement in
connection with the transfer or sale of all or substantially all of its assets
or business or its merger or consolidation with another company, so long as (1)
such acquirer or successor in interest agrees in writing to be bound by the
Agreement, and (2) the Company gives Novartis written notice of any such
assignment and 15 days to object thereto. Novartis may object to an assignment
only if such acquirer or successor in interest (a) is a direct competitor of
Novartis, or (b) prior to February 5, 2005, in Novartis' reasonable discretion,
is not a manufacturer which has a proven record of operational quality at least
equal to that of the Company or does not have sufficient financial wherewithal.
A copy of the Agreement, the promissory note, and the security agreement are
filed as exhibits to this Form 10-QSB.
In conjunction with the signing of the Agreement, the Company entered
into a non binding Letter of Intent with Novartis to enter into a purchase
agreement through which Novartis shall purchase certain manufacturing equipment
from the Company for approximately $900,000. The Letter of Intent shall be in
effect until midnight September 30, 2004 (US Eastern Standard Time). The
manufacturing equipment will remain with the Company until it has satisfied
its supply obligation to Novartis.
I-9
ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION
THREE AND SIX MONTHS ENDED JUNE 30, 2004 AND 2003
RESULTS OF OPERATIONS
Net sales for the second quarter of 2004 were $1,520,146 compared to net
sales of $1,624,416 for the second quarter of 2003, a decrease of $104,270, or
6.4%. For the first six months of 2004, net sales increased $729,340, or 22.3%
to $3,999,446 compared to net sales of $3,270,106 for the first six months of
2003. The decrease in net sales for the second quarter was attributable to lower
contract manufacturing sales from three customers for which the Company does not
anticipate any future orders, partially offset by higher contract manufacturing
net sales from the Company's largest customer. The increase in net sales for the
first six months of 2004, resulted primarily from higher sales to the Company's
largest customer due to product acceptance and a stronger cough/cold season. Net
sales of therapeutic branded consumer products for the three and six month
periods ended June 30, 2004 compared to the same periods in 2003, were lower
because the Company no longer manufactures these products and is selling off
remaining inventory. The Company expects net sales of therapeutic branded
consumer products to be minimal during the manufacturing wind down period (see
"Wind Down of Manufacturing Operations" below).
Gross profit for the second quarter of 2004 was $373,274, compared to
$391,007 for the second quarter of 2003, a decrease of 4.5%. Gross profit as a
percent of net sales for the second quarter of 2004 was 24.6% compared to 24.1%
for the second quarter of the prior year. Gross profit for the first six months
of 2004 was $1,119,039, compared to $882,306 for the first six months of 2003,
an increase of 26.8%. Gross profit as a percent of net sales for the first six
months of 2004 was 28.0% compared to 27.0% for the same period in 2003. The
decrease in gross profit dollars for the second quarter of 2004 is attributable
to lower contract manufacturing sales volume coupled with some changes in
customer mix. The increase in gross profit dollars for the first six months of
2004 resulted primarily from the increased contract manufacturing sales volume.
The increase in gross profit as a percentage of net sales for the second quarter
and first six months of 2004 resulted primarily from lower inventory
obsolescence costs offset in part by accruals in 2004 for employee severance
costs related to the manufacturing wind down (see "Wind Down of Manufacturing
Operations" below).
Sales and marketing expenses were $31,103 and $165,598 during the second
quarters of 2004 and 2003, and as a percentage of net sales, were 2.0% and
10.2%, respectively. Sales and marketing expenses were $99,051 and $363,675 for
the first six months of 2004 and 2003, and as a percentage of net sales, were
2.5% and 11.1%, respectively. The decreases in sales and marketing expenses for
the second quarter and first six months of 2004 were primarily due to reductions
in salaries and related benefits, travel expenditures, broker commissions and
other retail-related costs, and the elimination of advertising expenses, as the
Company retrenched to a position of supporting the contract manufacturing
business that reduced the sales force and consolidated the consumer and contract
marketing efforts. Currently the Company has no employee sales force and
operates with a staff of one part time sales/customer service employee. The
Company anticipates sales and marketing expenditures will continue to decrease
during the manufacturing wind down period (see "Wind Down of Manufacturing
Operations" below).
General and administrative expenses were $219,105 and $555,430 during the
second quarters of 2004 and 2003, and as a percentage of net sales, were 14.4%
and 34.2%, respectively. General and administrative expenses were $670,006 and
$1,037,795 for the first six months of 2004 and 2003, and as a percentage of net
sales, were 16.8% and 31.7%, respectively. The decreases in general and
administrative expenses for the second quarter and first six months of 2004 were
primarily due to declines in headcount, consulting costs, corporate legal fees,
travel and entertainment expenses, building depreciation and bad debt expense,
and the reversal of compensation expense booked during the first quarter of 2004
related to re-priced stock options outstanding (see Note 8 of Notes to Condensed
Financial Statements in Item 1 of this Report). The reductions in expenses were
partially offset by accruals for employee severance costs. The Company
anticipates general and administrative expenditures will continue to decrease
during the manufacturing wind down period (see "Wind Down of Manufacturing
Operations" below).
Research and development expenses for the second quarters of 2004 and 2003
were $121,561 and $97,249, and as a percentage of net sales, were 8.0% and 6.0%,
respectively. Research and development expenses for the first six months of 2004
and 2003 were $268,801 and $198,781, and as a percentage of net sales, were 6.7%
and 6.1%, respectively. The increases in research and development expenses for
the
I-10
second quarter and first six months of 2004 resulted primarily from an increase
in patent-related legal costs and accruals for employee severance costs, which
were offset in part by decreases in headcount and compensation related expenses
due to staff turnover and the reversal of compensation expense recorded during
the first quarter of 2004 related to re-priced stock options outstanding (see
Note 8 of Notes to Condensed Financial Statements in Item 1 of this Report). The
Company anticipates research and development expenditures will decrease during
the manufacturing wind down period (see "Wind Down of Manufacturing Operations"
below).
During the six months ended June 30, 2003, the Company recorded a loss of
$52,375 on the February 2003 sale and leaseback of its Minnetonka, Minnesota
corporate facility. The Company also repaid an outstanding mortgage note payable
in connection with the building sale (see Note 7 of Notes to Condensed Financial
Statements in Item 1 of this Report).
Interest expense declined in the second quarter of 2004 to $5,181 from
$5,721 in the second quarter of 2003 and declined in the first six months of
2004 to $9,972 from $24,653 for the same period in the prior year. The declines
resulted primarily from the absence of mortgage interest in connection with the
sale of the Minnetonka, Minnesota corporate facility in February 2003. Net other
income (expense) increased in the second quarter of 2004 to $12,515 from ($557)
in the second quarter of 2003. For the first six months of 2004 net other income
was $12,357 compared to net other income of $1,939 for the first six months of
2003. The increase in net other income resulted primarily from the sale of some
excess shelving the Company no longer needed.
The Company recorded net income of $8,839 for the second quarter of 2004
compared to a net loss of $433,548 for the second quarter of 2003. For the first
six months of 2004, the Company recorded a net income of $83,566 compared to a
net loss of $793,034 for the same period in the prior year. The improvement in
net income (loss) was primarily the result of higher contract manufacturing
sales coupled with lower operating expenses resulting from the shift in focus to
contract manufacturing and other cost reduction efforts.
No federal or state income taxes were provided for the second quarter or
first six months of 2004, due to available tax credit and net operating loss
carryforwards to the current periods. The provision for income tax benefits for
the second quarter and first six months of 2004 and 2003 was offset principally
by a valuation allowance for deferred taxes.
Inflation has not had a significant impact on the Company's operations or
cash flow.
LIQUIDITY AND CAPITAL RESOURCES
Cash and cash equivalents increased by $407,798 during the first six
months of 2004 to $891,642 at June 30, 2004. The increase in cash and cash
equivalents during the first six months of 2004 was due to cash provided by
operating activities of $501,020. Trade and other receivables decreased $203,214
during the first six months of 2004 to $652 at June 30, 2004, primarily due to
lower branded consumer products sales and collection of outstanding balances.
Inventories decreased by $256,604 during the first six months of 2004 to
$836,865 at June 30, 2004, from $1,093,469 at December 31, 2003, due primarily
to the shipment of several lots of contract manufacturing finished goods in
January and February 2004 which were produced in the fourth quarter of 2003.
Accounts payable decreased $118,032 during the first six months of 2004 to
$218,717 at June 30, 2004, from $336,749 December 31, 2003, primarily due to the
timing of inventory purchases and raw material receipts.
During the second quarter of 2004, the Company purchased a piece of
equipment it had previously been leasing for a fair market lease buy out of
$74,550. There were no future material commitments for capital expenditures at
June 30, 2004. Investments in patents and intellectual property was $31,473 for
the first half of 2004 relating to expanding the coverage area for the Company's
patent portfolio. Cash used in financing activities totaled $12,801 for the
first half of 2004, due to the receipt of $18,707 in proceeds related to
exercises of stock options and repayment of long-term capital lease obligations
of $5,906.
The Company had a working capital deficit of $606,103 and a current ratio
of 0.75 at June 30, 2004 compared to a working capital deficit of $779,988 and a
current ratio of 0.72 at December 31, 2003. The
I-11
improvement in working capital deficit and current ratio during the first six
months of 2004 is primarily attributable to higher cash and cash equivalents and
lower inventory levels coupled with lower customer deposits when compared to
December 31, 2003.
On July 19, 2004, the Company entered into a new supply and licensing
agreement with Novartis, effective January 1, 2004. See the discussion under
"Subsequent Event" in Note 11 of Part I, Item 1 above for a description of this
new agreement. Under the Agreement, the Company will continue to receive advance
payments against future orders. At June 30, 2004, the amount owed to Novartis
under product prepayment deposits was $1,342,317. The Company has also been
receiving advance product payments from other customers. Maintaining adequate
levels of working capital to support the Company's manufacturing operations has
been and will be dependent upon the continuation of these advance product
payments.
WIND DOWN OF MANUFACTURING OPERATIONS
In September 2003, the Company learned that, as a result of a change in
its internal supplier selection criteria, Novartis intends to stop using the
Company as a contract manufacturer for its topical patches during the fourth
quarter of 2004. In addition, Johnson & Johnson Consumer Products Company, the
Company's second largest customer, has indicated that it also intends to stop
using the Company as a contract manufacturer during the third quarter of 2004.
Novartis and Johnson & Johnson accounted for approximately 55% and 16% of the
Company's net sales for the year ended December 31, 2003. Based on these
anticipated changes, the Board of Directors has determined that the Company will
wind down its manufacturing operations.
On July 19, 2004, in preparation for the wind down of its manufacturing
operations, the Company entered into a new supply and licensing agreement with
Novartis, effective January 1, 2004. See the discussion under "Subsequent Event"
in Note 11 of Part I, Item 1 above for a description of this new agreement.
It is management's intent to wind down its manufacturing operations, sell
off manufacturing assets, renegotiate its facility leases and fund continuing
operations with licensing fees and royalty income from licensing agreements or
from other income derived from protection of rights pertaining to the Company's
intellectual property. However, there can be no assurance that the Company will
be successful in the wind down of manufacturing operations, selling off the
manufacturing assets, renegotiating its manufacturing facility leases, or in the
protection of the Company's rights related to intellectual property. There can
also be no assurance that future licensing fees and royalty income, if any, will
be sufficient to fund future operations.
The Company currently believes that it will be able to wind down and exit
its manufacturing operations and facility lease obligations without defaulting
on its contractual obligations to any contract manufacturing customer. However,
there can be no assurance that the Company will be able to exit manufacturing or
its facility leases without defaulting on contractual obligations or other debts
which become due and payable.
In connection with the pending cessation of manufacturing operations, the
Company has implemented employee reduction and retention programs to reduce the
number of employees needed to support the wind down of manufacturing operations
while retaining those employees who are critical to that process and to managing
the Company's ongoing licensing agreements and intellectual property portfolio.
The Company currently has 25 full time and one part time employee. The Company
is exploring its alternatives with respect to the sale of its manufacturing
assets, the renegotiation or termination of its leases and other contractual
obligations, and other adjustments resulting directly from its exit from
manufacturing operations. In addition, the Company will be considering other
possible fundamental changes in future periods that could include, among other
things, a sale of its remaining assets or of the business as a whole.
The Company believes its existing cash and cash equivalents may not be
sufficient to fund operations through 2004. The Company currently does not have
any new or additional committed sources of capital or financing identified, and
there can be no assurance that additional funding will be available in a timely
manner, on acceptable terms, or at all. In addition, the Company may not be
successful in winding down its manufacturing operations without defaulting on
its existing contractual obligations, and may require additional funds for its
ongoing operations during the wind down period. If adequate funds are not
available,
I-12
the Company may be forced to further scale-back, eliminate certain aspects of or
cease operations entirely in the near future, or attempt to obtain funds through
unfavorable arrangements with partners or others that may require the Company to
relinquish rights to certain technologies or potential markets or which
otherwise may be materially unfavorable to the Company. The survivability of the
Company is also dependant upon the Company continuing to receive cash under the
prepayment agreement it has with the Company's largest customer. All these
factors, among others, raise substantial doubt about the Company's ability to
continue as a going concern. The Company's continuation as a going concern is
dependent upon its ability to generate sufficient cash flow to meet its
obligations on a timely basis, to continue to receive prepayment from the
Company's largest customer, to obtain additional funding as may be required, and
ultimately to attain successful operations.
ITEM 3 - CONTROLS AND PROCEDURES
Under the supervision and with the participation of our management,
including our principal executive officer and principal financial officer, we
have evaluated the effectiveness of the design and operation of our disclosure
controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the
Securities Exchange Act of 1934 (the "Exchange Act")). Based upon this
evaluation, the principal executive officer and principal financial officer have
concluded that, as of the end of the period covered by this report, our
disclosure controls and procedures were effective in timely alerting them to the
material information relating to the Company required to be included in the
reports we file or submit under the Exchange Act.
During the quarter ended June 30, 2004, there were no changes in the
Company's internal control over financial reporting (as defined in Rule
13a-15(f) under the Exchange Act) that has materially affected, or is reasonably
likely to materially affect, the Company's internal control over financial
reporting.
I-13
PART II - OTHER INFORMATION
ITEM 1 - LEGAL PROCEEDINGS
None.
ITEM 2 - CHANGES IN SECURITIES AND SMALL BUSINESS ISSUER PURCHASES OF EQUITY
SECURITIES
None.
ITEM 3 - DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None.
ITEM 5 - OTHER INFORMATION
None.
ITEM 6 - EXHIBITS AND REPORTS ON FORM 8-K
(a) EXHIBITS
Exhibit No. Description
----------- ------------------------------------------------------
3.01 Articles of Incorporation of LecTec Corporation, as
amended (Incorporated herein by reference to the
Company's Form S-1 Registration Statement (file number
33-9774C) filed on October 31, 1986 and amended on
December 12, 1986).
3.02 Bylaws of LecTec Corporation (Incorporated herein by
reference to the Company's Form S-1 Registration
Statement (file number 33-9774C) filed on October 31,
1986 and amended on December 12, 1986).
*10.01 Supply and License Agreement By and Between LecTec
Corporation and Novartis Consumer Health, Inc. executed
on July 19, 2004 and effective as of January 1, 2004,
filed herewith.
10.02 Promissory Note By and Between LecTec Corporation and
Novartis Consumer Health, Inc. executed on July 19, 2004
and effective as of January 1, 2004, filed herewith.
10.03 Security Agreement By and Between LecTec Corporation
and Novartis Consumer Health, Inc. executed on July 19,
2004 and effective as of January 1, 2004, filed herewith.
31.01 Certification of Chief Executive Officer Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002, filed
herewith.
31.02 Certification of Acting Chief Financial Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of
2002, filed herewith.
II-1
32.01 Chief Executive Officer and Acting Chief Financial
Officer Certification Pursuant to 18 U.S.C. Section
1350, as Adopted Pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, filed herewith.
99.01 Cautionary Statements (Incorporated herein by
reference to Exhibit 99.01 to the Company's Report on
Form 10-KSB for the fiscal year ended December 31,
2003).
Exhibit Notes:
* Confidential treatment has been requested for portions
of this Exhibit pursuant to Rule 24b-2 under the
Securities Exchange Act of 1934 as amended. The
confidential portions have been deleted and filed
separately with the Securities and Exchange
Commission.
(b) REPORTS ON FORM 8-K
One Current Report on Form 8-K was filed by the Company during the
quarter ended June 30, 2004, concerning a change in the Company's
independent accountants.
The Form 8-K, filed April 23, 2004, reported that, effective April
19, 2004, the Board of Directors of the Company dismissed its independent
accountants, Grant Thornton LLP, and appointed Lurie Besikof Lapidus &
Company, LLP as its new independent accountants. The decision to change
accountants was approved by the Company's Board of Directors upon the
recommendation of its Audit Committee.
II-2
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.
LECTEC CORPORATION
Date August 16, 2004 By /s/ Timothy P. Fitzgerald
--------------- -----------------------------
Timothy P. Fitzgerald
Chief Executive Officer & President
(principal financial officer and
duly authorized officer)
II-3